Introduction The first glucagon-like peptide-1 receptor agonist (GLP-1) for type 2 diabetes mellitus (T2DM) was approved in 2005 and for chronic weight management in 2014
Lee's Pharmaceutical Holdings Ltd
Modern sedentary activities promote overconsumption of food in our current obesogenic environment
Our lifestyle at home, school and work tends to be sedentary. The bigger question, she says, is whether people will need to stay on GLP-1 drugs indefinitely
The workaround many prescribers use: if a non-diabetic patient also has a comorbidity that a GLP-1 drug treats (cardiovascular disease for Wegovy, sleep apnea for Zepbound), the prescriber can request coverage under that indication
Discussion In the short term, the high price of GLP-1 medications poses a significant challenge for many people, particularly those from lower-income backgrounds and marginalized communities